|
[1]AKINYEMIJU T, ABERA S, AHMED M, et al.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level:Results from the global burden of disease study 2015[J].JAMA Onclo, 2017, 3 (12) :1683-1691.
|
|
[2]CHEN WQ, ZHENG RS, ZHANG SW, et al.Report of cancer incidence and mortality in China, 2013[J].China Cancer, 2016, 26 (1) :1-7. (in Chinese) 陈万青, 郑荣寿, 张思维, 等.2013年中国恶性肿瘤发病和死亡分析[J].中国肿瘤, 2016, 26 (1) :1-7.
|
|
[3]LIM C, BHANGUI P, SALLOUM C, et al.Impact of time to surgery in the outcome of patients with liver resection for BCLC 0-A stage hepatocellular carcinoma[J].J Hepatol, 2017.[Epub ahead of print]
|
|
[4]HANAHAN D, WEINBERG RA.Hallmarks of cancer:The next generation[J].Cell, 2011, 144 (5) :646-474.
|
|
[5]ABELEV GI.Production of embryonal serum alpha-globulin by hepatomas:Review of experimental and clinical data[J].Cancer Res, 1968, 28 (7) :1344-1350.
|
|
[6]KIM JU, SHARIFF MI, CROSSEY MM, et al.Hepatocellular carcinoma:Review of disease and tumor biomarkers[J].World J Hepatol, 2016, 8 (10) :471-484.
|
|
[7]SONG P, FENG X, INAGAKI Y, et al.Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China:A multi-center case-controlled study of 1153 subjects[J].Biosci Trends, 2014, 8 (5) :266-273.
|
|
[8]SAUZAY C, PETIT A, BOURGEOIS AM, et al.Alpha-foetoprotein (AFP) :A multi-purpose marker in hepatocellular carcinoma[J].Clin Chim Acta, 2016, 463:39-44.
|
|
[9]CAVIGLIA GP, ABATE ML, PETRINI E, et al.Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection[J].Hepatol Res, 2016, 46 (3) :e130-e135
|
|
[10]GAO J, SONG P.Combination of triple biomarkers AFP, AFP-L3, and PIVAKII for early detection of hepatocellular carcinoma in China:Expectation[J].Drug Discov Ther, 2017, 11 (3) :168-169.
|
|
[11]LU LG.Advances in early screening and diagnosis of hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (7) :1257-1261. (in Chinese) 陆伦根.原发性肝癌的早期筛查及诊断[J].临床肝胆病杂志, 2017, 33 (7) :1257-1261.
|
|
[12]WISHART DS.Is cancer a genetic disease or a metabolic disease?[J].Ebiomedicine, 2015, 23, 2 (6) :478-479.
|
|
[13]LIU Y, YE N, GONG JP.Research advances in prevention and treatment of primary liver cancer with metabolic agents[J].J Clin Hepatol, 2016, 32 (7) :1413-1417. (in Chinese) 刘彦, 叶楠, 龚建平.代谢类药物治疗和预防原发性肝癌的研究进展[J].临床肝胆病杂志, 2016, 32 (7) :1413-1417.
|
|
[14]YANG Y, LI C, NIE X, et al.Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning1H NMR spectroscopy in conjunction with multivariate data analysis[J].J Proteome Res, 2007, 6 (7) :2605-2614.
|
|
[15]RESSOM HW, XIAO JF, TULI L, et al.Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis[J].Anal Chim Acta, 2012, 743:90-100.
|
|
[16]WANG B, CHEN D, CHEN Y, et al.Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry[J].J Proteome Res, 2012, 11 (2) :1217-1227.
|
|
[17]FURUYA H, SHIMIZU Y, KAWAMORI T.Sphingolipids in cancer[J].Cancer Metastasis Rev, 2011, 30 (3-4) :567-576.
|
|
[18]FITIAN AI, NELSON DR, LIU C, et al.Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS[J].Liver Int, 2014, 34 (9) :1428-1444.
|
|
[19]PATTERSON AD, MAURHOFER O, BEYOGLU D, et al.Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling[J].Cancer Res, 2011, 71 (21) :6590-6600.
|
|
[20]XIAO JF, VARGHESE RS, ZHOU B, et al.LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort[J].J Proteome Res, 2012, 11 (12) :5914-5923.
|
|
[21]LUO P, YIN P, HUA R, et al.A large-scale, multi-center serum metabolite biomarkers identification study for the early detection of hepatocellular carcinoma[J].Hepatology, 2017.[Epub ahead of print]
|
|
[22]di POTO C, FERRARINI A, ZHAO Y, et al.Metabolomic characterization of hepatocellular carcinoma in patients with liver cirrhosis for biomarker discovery[J].Cancer Epidemiol Biomarkers Prev, 2017, 26 (5) :675-683.
|
|
[23]GAO R, CHENG J, FAN C, et al.Serum metabolomics to identify the liver disease-specific biomarkers for the progression of hepatitis to hepatocellular carcinoma[J].Sci Rep, 2015, 5:18175.
|
|
[24]GONG ZG, ZHAO W, ZHANG J.Metabolomics and eicosanoid analysis identified serum biomarkers for distinguishing hepatocellular carcinoma from hepatitis B virus-related cirrhosis[J].Oncotarget, 2017, 8 (38) :63890-63900.
|
|
[25]ZHANG J, HAO N, LIU W, et al.In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery[J].Br J Cancer, 2017, 117 (11) :1676-1684.
|
|
[26]SANABRIA JR, KOMBU RS, ZHANG GF.Glutathione species and metabolomic prints in subjects with liver disease as biological markers for the detection of hepatocellular carcinoma[J].HPB (Oxford) , 2016, 18 (12) :979-990.
|
|
[27]SOGA T, SUGIMOTO M, HONMA M, et al.Serum metabolomics revealsγ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease[J].J Hepatol, 2011, 55 (4) :896-905.
|
|
[28]YANG L, YUE S, YANG L, et al.Sphingosine kinase/sphingosine1-phosphate (S1P) /S1P receptor axis is involved in liver fibrosis-associated angiogenesis[J].J Hepatol, 2013, 59 (1) :114-123.
|
|
[29]MEYER K, JIA Y, GAO WQ, et al.Expression of peroxisome proliferator-activated receptor alpha, and PPARalpha regulated genes in spontaneously developed hepatocellular carcinomas in fatty acyl-Co A oxidase null mice[J].Int J Oncol, 2002, 21 (6) :1175-1180.
|
|
[30]JAIN M, NILSSON R, SHARMA S, et al.Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation[J].Science, 2012, 336 (6084) :1040-1044.
|
|
[31]CHANETON B, HILLMANN P, ZHENG L, et al.Serine is a natural ligand and allosteric activator of pyruvate kinase M2[J].Nature, 2012, 491 (7424) :458-462.
|
|
[32]WU FX, WANG Q, ZHANG ZM, et al.Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy[J].Cancer Lett, 2009, 279 (2) :163-170.
|
|
[33]MITTAL D, GUBIN MM, SCHREIBER RD, et al.New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape[J].Curr Opin Immunol, 2014, 27:16-25.
|
DownLoad: